---
title: "Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Indication questions"
description: "Indication questions on Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Eligibility. Questions: Is Shingrix approved for immunocompromised adults 18 and older? Is Shingrix indicated to prevent postherpetic neuralgia in adults 50 and older? Shingrix: which adults 50 and older are at higher risk of shingles? Shingrix: what is the lifetime risk of shingles? 1 further question follow. 5 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Indication questions

Manufacturer: GlaxoSmithKline Biologicals; GlaxoSmithKline  
Prescribing information: [Shingrix](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF)

Indication questions that apply to every indication of Shingrix are on [Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications: Indication](https://www.evicenter.com/medical-information/shingrix/indication).

## Indication

<a id="shingrix-immunocompromised-indication"></a>

### Is Shingrix approved for immunocompromised adults 18 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles) in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.”

Source: [SHINGRIX: IC Patients 18+, captured 2026-11-14](https://shingrixhcp.com/home-ic/#:~:text=SHINGRIX%20is%20a%20vaccine%20indicated,by%20known%20disease%20or%20therapy.)

> “SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).”

Source: [SHINGRIX: IC Patients 18+, captured 2026-11-14](https://shingrixhcp.com/home-ic/#:~:text=SHINGRIX%20is%20not%20indicated%20for%20prevention%20of%20primary%20varicella%20infection%20%28chickenpox%29.)

<a id="shingrix-complications-indication"></a>

### Is Shingrix indicated to prevent postherpetic neuralgia in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “SHINGRIX is not indicated for the prevention of postherpetic neuralgia (PHN) or other herpes zoster-related complications.<sup>7</sup>”

Source: [SHINGRIX: Support for Nurses, captured 2026-11-14](https://shingrixhcp.com/pharmacists-nurses/support-nurses/#:~:text=SHINGRIX%20is%20not%20indicated%20for,%28PHN%29%20or%20other%20herpes%20zoster%2Drelated)

## Eligibility

<a id="shingrix-risk-factors-50-and-older"></a>

### Shingrix: which adults 50 and older are at higher risk of shingles?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Starting at 50 years old, shingles risk sharply increases<sup>1</sup>
>
> Increasing age can lead to a natural decline in VZV-specific immunity<sup>1</sup>”

Source: [SHINGRIX: Shingles Risk Factors & Comorbidities, captured 2026-11-14](https://shingrixhcp.com/about-shingles/risk-factors-comorbidities/#:~:text=Starting%20at%2050%20years%20old%2C,a%20natural%20decline%20in%20VZV%2Dspecific)

> “Patients ≥50 years old may have additional risk factors: certain comorbidities and psychological stress have been associated with increased risk of shingles<sup>4,†</sup>
> DIABETES
>
> 24
>
> %
>
> INCREASED RISK in patients with DIABETES vs without
>
> 32 studies, pooled effect estimate:
> RR: 1.24 (95% CI: 1.14-1.35)
>
> CHRONIC KIDNEY DISEASE
>
> 29
>
> %
>
> INCREASED RISK in patients with CHRONIC KIDNEY DISEASE vs without
>
> 18 studies, pooled effect estimate:
> RR: 1.29 (95% CI: 1.10-1.51)
>
> CARDIOVASCULAR CONDITIONS
>
> 34
>
> %
>
> INCREASED RISK in patients with
> CARDIOVASCULAR CONDITIONS<sup>‡</sup> vs without
>
> 16 studies, pooled effect estimate:
> RR: 1.34 (95% CI: 1.17-1.54)
>
> PSYCHOLOGICAL STRESS
>
> 47
>
> %
>
> INCREASED RISK in patients with PSYCHOLOGICAL STRESS<sup>§</sup> vs without
>
> 8 studies, pooled effect estimate:
> RR: 1.47 (95% CI: 1.03-2.10)
>
> †
>
> Data from a meta-analysis assessing risk factors for HZ. The analysis included a total study population of 198,751,846 individuals, with 3,768,691 HZ cases across 88 studies (68 cohort and 20 case-control studies) from 1966 to 2019. The populations in these studies ranged from people aged 3 months to 104 years old.<sup>‖</sup> Eighteen risk factors were identified in the meta-analysis, note not all are presented here. Limitations included the following: most studies were observational and had a higher likelihood of bias; the majority of studies used administrative data, which is subject to miscoding, errors, and can vary between practitioners; finally, heterogeneity was high across studies. This list is not exhaustive and may not present all conditions associated with an increased risk of HZ.<sup>4</sup>
>
> ‡
>
> Cardiovascular conditions included in each individual study in the meta-analysis varied by study and included heart disease, heart failure, hypertension, hyperlipidemia, stroke, atrial fibrillation/flutter, and other cardiovascular disease.<sup>4</sup>
>
> §
>
> The methodology used to define psychological stress varied greatly across studies and included patient questionnaires and major life events (either self-reported or captured on medical record, eg, death of a spouse or diagnosis of major medical event).<sup>4</sup>
>
> ‖
>
> SHINGRIX is a vaccine indicated for prevention of HZ (shingles) in adults aged 50 years and older.<sup>3</sup>
>
>
>
>
> Cl=confidence interval; COPD=chronic obstructive pulmonary disease; RR=relative risk; VZV=varicella zoster virus.”

Source: [SHINGRIX: Shingles Risk Factors & Comorbidities, captured 2026-11-14](https://shingrixhcp.com/about-shingles/risk-factors-comorbidities/#:~:text=Patients%20%E2%89%A550%20years%20old%20may,RR%3Drelative%20risk%3B%20VZV%3Dvaricella%20zoster%20virus.)

Note: The relative risks are pooled estimates from a meta-analysis of mostly observational studies (Marra et al., 2020); the footnote lists its limitations. The meta-analysis included people of all ages, so the estimates are not specific to adults 50 and older.

<a id="shingrix-lifetime-risk"></a>

### Shingrix: what is the lifetime risk of shingles?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Nearly everyone ≥50 years of age is at risk for shingles, no matter how healthy they feel.<sup>3,4</sup>”

Source: [SHINGRIX: Support for Nurses, captured 2026-11-14](https://shingrixhcp.com/pharmacists-nurses/support-nurses/#:~:text=Nearly%20everyone%20%E2%89%A550%20years%20of,no%20matter%20how%20healthy%20they)

> “1 in 3 people will develop shingles in their lifetime.<sup>5</sup>”

Source: [SHINGRIX: Support for Nurses, captured 2026-11-14](https://shingrixhcp.com/pharmacists-nurses/support-nurses/#:~:text=1%20in%203%20people%20will%20develop%20shingles%20in%20their)

Note: The 1 in 3 figure is a lifetime risk for people in general, cited on the Support for Nurses page of the Shingrix HCP site to a CDC clinical overview of shingles.

<a id="shingrix-risk-immunocompromised"></a>

### Shingrix: which immunocompromised adults are at increased risk of shingles?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “The risk for shingles is increased in patients with hematologic malignancies, like Hodgkin lymphoma<sup>1</sup>”

Source: [SHINGRIX: Patient Profiles, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/patient-profiles/#:~:text=The%20risk%20for%20shingles%20is,with%20hematologic%20malignancies%2C%20like%20Hodgkin)

> “Patients with solid tumors who are or will be on immunosuppressive therapy are at an increased risk for shingles<sup>1</sup>”

Source: [SHINGRIX: Patient Profiles, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/patient-profiles/#:~:text=Patients%20with%20solid%20tumors%20who,at%20an%20increased%20risk%20for)

> “Data show that people living with HIV have an increased risk for shingles<sup>1</sup>”

Source: [SHINGRIX: Patient Profiles, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/patient-profiles/#:~:text=Data%20show%20that%20people%20living%20with%20HIV%20have%20an%20increased%20risk%20for)

> “Patients ≥18 years on immunosuppressive therapy are at an increased risk for shingles<sup>2</sup>”

Source: [SHINGRIX: Patient Profiles, captured 2026-11-14](https://shingrixhcp.com/home-ic/who-to-vaccinate/patient-profiles/#:~:text=Patients%20%E2%89%A518%20years%20on%20immunosuppressive%20therapy%20are%20at%20an%20increased%20risk%20for)

> “Explain that in people who are immunocompromised, the rash tends to be more severe, with a prolonged duration, and the risk of potentially serious shingles-related complications is greater<sup>1</sup>”

Source: [SHINGRIX: Patient Counseling, captured 2026-11-14](https://shingrixhcp.com/home-ic/in-your-practice/patient-counseling/#:~:text=Explain%20that%20in%20people%20who,potentially%20serious%20shingles%2Drelated%20complications%20is)

Note: The first four passages are from patient profiles (not actual patients) on the Patient Profiles page of the immunocompromised section of the Shingrix HCP site; the last is from its Patient Counseling page.

## Related pages
- [Medical information: Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention)
- [Clinical trials](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/safety)
- [Specific populations](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/guidelines)
